Prognostic Significance of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography in Anal Squamous Cell Carcinoma: A Systematic Review and a Meta-Analysis.

Ramin Sadeghi, Sara Harsini, Mohammad Ali Qodsi Rad, Vahid Reza Dabbagh, Giorgio Treglia

Journal: Contrast media & molecular imaging 2019;2018():9760492

PMID: 30627062

Abstract

PURPOSE

Prognostic significance of fluorine-18 fluorodeoxyglucose positron emission tomography (F-FDG-PET) in anal squamous cell carcinoma (SCC) has been evaluated in several studies; however, the results seem to be controversial and no consensus exists about its predictive capability. The current meta-analysis was carried out to comprehensively investigate the prognostic significance of F-FDG-PET parameters in patients with anal SCC.

METHODS

A comprehensive literature search of PubMed/MEDLINE and Scopus databases was performed to retrieve pertinent articles published until August 5th 2018, concerning the prognostic significance of F-FDG-PET in patients with anal SCC. No language restriction was used. Several prognostic factors were reported for progression-free survival (PFS) and overall survival (OS) including pretreatment maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), inguinal nodal uptake, and metabolic response to therapy.

RESULTS

Eleven studies (741 patients) were included. The pooled hazard ratio (HR) for the probability of PFS was 5.36 (95% confidence interval (95% CI): 3.12-9.21, < 0.001) for metabolic response to therapy and 1.98 (95% CI: 1.26-3.12, =0.003) for SUVmax. The pooled HR for the probability of OS was 5.87 (3.02-11.39, < 0.0001) for metabolic response to therapy. On the other hand, the study revealed that the pooled HRs of MTV and inguinal nodal uptake for PFS were 1.56 (95% CI: 0.96-2.53, =0.072) and 1.79 (95% CI: 1-3.21, =0.051), respectively.

CONCLUSIONS

Our findings propose that some F-FDG-PET parameters could serve as prognostic indicators in anal SCC, but further larger studies are needed in this setting.

Address: Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.; Association of Nuclear Medicine and Molecular Imaging (ANMMI), Universal Scientific Education and Research Network (USERN), Tehran, Iran.; Students' Scientific Research Center (SSRC), Tehran University of Medical Sciences, Tehran, Iran.; Research Center for Nuclear Medicine, Dr. Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.; Nuclear Medicine Department, Shohadaye Tajrish Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.; Clinic of Nuclear Medicine and PET/CT Center, Ente Ospedaliero Cantonale, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.; Health Technology Assessment Unit, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.; Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, Lausanne, Switzerland.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.